These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19226552)

  • 1. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.
    Grillberger L; Kreil TR; Nasr S; Reiter M
    Biotechnol J; 2009 Feb; 4(2):186-201. PubMed ID: 19226552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII.
    Mannully ST; L N R; Pulicherla KK
    Int J Biol Macromol; 2018 Nov; 119():496-504. PubMed ID: 30063930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choice of replacement therapy for hemophilia: recombinant products only?
    Mannucci PM; Giangrande PL
    Hematol J; 2000; 1(2):72-6. PubMed ID: 11920173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manufacturing of recombinant therapeutic proteins in microbial systems.
    Graumann K; Premstaller A
    Biotechnol J; 2006 Feb; 1(2):164-86. PubMed ID: 16892246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consideration in hemophilia therapy selection.
    Pipe S
    Semin Hematol; 2006 Apr; 43(2 Suppl 3):S23-7. PubMed ID: 16631824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of recombinant protein therapeutics in cultivated mammalian cells.
    Wurm FM
    Nat Biotechnol; 2004 Nov; 22(11):1393-8. PubMed ID: 15529164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII--Baxter: rAHF-PFM, recombinant anti-haemophilic factor--protein-free method, recombinant factor VIII--protein-free.
    Drugs R D; 2003; 4(6):366-8. PubMed ID: 14584967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioprospecting in plants for engineered proteins.
    Joshi L; Lopez LC
    Curr Opin Plant Biol; 2005 Apr; 8(2):223-6. PubMed ID: 15753005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.
    Ewenstein BM; Collins P; Tarantino MD; Negrier C; Blanchette V; Shapiro AD; Baker D; Spotts G; Sensel M; Yi SE; Gomperts ED
    Semin Hematol; 2004 Jan; 41(1 Suppl 2):1-16; discussion 16-8. PubMed ID: 15071785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production processes of licensed recombinant factor VIII preparations.
    Boedeker BG
    Semin Thromb Hemost; 2001 Aug; 27(4):385-94. PubMed ID: 11547361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New-generation recombinant factor concentrates: bridge to gene therapy.
    Ragni MV
    Haemophilia; 2001 Jan; 7 Suppl 1():28-35. PubMed ID: 11240616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell culture process operations for recombinant protein production.
    Abu-Absi S; Xu S; Graham H; Dalal N; Boyer M; Dave K
    Adv Biochem Eng Biotechnol; 2014; 139():35-68. PubMed ID: 24153406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency.
    Pham PL; Perret S; Doan HC; Cass B; St-Laurent G; Kamen A; Durocher Y
    Biotechnol Bioeng; 2003 Nov; 84(3):332-42. PubMed ID: 12968287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manufacturing challenges in the commercial production of recombinant coagulation factor VIII.
    Jiang R; Monroe T; McRogers R; Larson PJ
    Haemophilia; 2002 Mar; 8 Suppl 2():1-5. PubMed ID: 11966844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?
    Josephson CD; Abshire T
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):441-6. PubMed ID: 16163220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating haemophilia A with recombinant blood factors: a comparison.
    Ananyeva N; Khrenov A; Darr F; Summers R; Sarafanov A; Saenko E
    Expert Opin Pharmacother; 2004 May; 5(5):1061-70. PubMed ID: 15155108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies.
    Chartrain M; Chu L
    Curr Pharm Biotechnol; 2008 Dec; 9(6):447-67. PubMed ID: 19075685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise and challenges of bioengineered recombinant clotting factors.
    Pipe SW
    J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.